Z Squared Inc. (ZSQR): Nasdaq/NYSE listing notice — Coeptis Therapeutics receives Nasdaq delisting notice for missing annual meeting; meeting set for Jan 30
Z Squared Inc.
Nasdaq letter on Jan 12, 2026 cites violation of Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold annual meeting within 12 months of fiscal year end (Dec 31, 2024).
Company has 45 days to submit compliance plan; if accepted, Nasdaq may grant exception until June 29, 2026.
Annual meeting scheduled for January 30, 2026, which Coeptis believes will cure the deficiency.
Z Squared Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)).
Exchange
nasdaq
Notice
deficiency notice
Rules
5620(a), 5810(c)(2)
Exact text from the filing
January 12, 2026, Coeptis Therapeutics Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Capital Market LLC (“Nasdaq”) indicating that the Company is in violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)G) due to the Company’s failure to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end of December 31, 2024 (the “Annual Meeting Rule”). Under Nasdaq Listing Rules, the Company has 45 calendar days from January 12, 2026 to submit a plan to regain compliance and, if Nasdaq accepts su
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.